Schiff Nutrition International Appoints Jon Fieldman as Senior Vice President - Operations
26 4월 2011 - 8:00PM
Business Wire
Schiff Nutrition International, Inc. (NYSE:WNI) announced that
it has appointed Jon Fieldman to the position of Senior Vice
President – Operations, effective May 10, 2011. Schiff also
announced the retirement of Thomas H. Elitharp, Executive Vice
President – Operations and Support Services. Fieldman will assume
Elitharp’s primary responsibilities upon his retirement.
“We are extremely pleased to have Jon join our team as the next
SVP – Operations,” stated Tarang Amin, president and chief
executive officer of Schiff Nutrition. “Jon is a proven leader who
has driven growth and operational excellence at Fortune 500
consumer product companies, including Clorox and General Mills. His
wide range of experience spans the global supply chain from
procurement through fulfillment. Jon will be a key player as we
execute on opportunities to grow the Schiff brand by expanding our
channel, product, and geographic presence. We also want to thank
Tom for his significant contributions to the success of Schiff
during his 13 years of service to the company, which included the
expansion of our high quality, state of the art manufacturing
facility in Salt Lake City.”
“Schiff has strong brands and is well positioned to move to a
new phase of growth,” said Jon Fieldman. “I am delighted to join
the company at this exciting time and look forward to leveraging my
extensive consumer product experience to help Schiff continue to
build a world-class nutritional supplements company.”
Fieldman, 41, brings 20 years of consumer products operations
experience to Schiff and has held positions in a range of operating
companies from food to specialty consumer product businesses. Most
recently he served as Vice President – Specialty Supply Chain for
the Clorox Company. In this role, he was responsible for $2.5
billion of business and established a track record of achieving
quality and innovation while driving low cost performance. He also
served in senior roles in manufacturing and supply chain planning.
Prior to joining Clorox, Fieldman worked for General Mills for
eight years where he held a variety of plant manufacturing
positions. Fieldman holds a bachelor’s degree with honors in
Industrial Engineering and Engineering Management from Stanford
University.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Move Free®, Schiff® Vitamins, MegaRed®, Mega-D3™, Tiger's
Milk® and Fi-Bar®. To learn more about Schiff, please visit the web
site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to:
dependence on sales of our Move Free product and the joint care
category, dependence on individual customers, adverse publicity or
consumer perception regarding our nutritional supplements and/or
their ingredients, similar products distributed by other companies
or the nutritional supplement industry generally, the impact of
competitive products and pricing pressure (including expansion of
private label products), the inability to successfully bid on new
and existing private label business, the impact of raw material
pricing, availability and quality (particularly relating to joint
care products and ingredients from third-party suppliers outside
the United States, including China), claims that our products
infringe the intellectual property rights of others, the inability
to enforce or protect our intellectual property rights and
proprietary techniques against infringement, the inability to
successfully launch and maintain sales (especially in the joint
care and omega-3 categories) outside of the United States while
maintaining the integrity of the products sold and complying with
local regulations, the inability to appropriately respond to
changing consumer preferences and demand for new products, the
inability to gain or maintain market distribution for new products
or product enhancements, litigation and government or
administrative regulatory action in the United States and
internationally, including FDA enforcement and product liability
claims, the inability or increased cost to obtain sufficient levels
of product liability and general insurance, the inability to comply
with existing or new regulations, both in the United States and
abroad, and adverse actions regarding product formulation, claims
or advertising, product recalls or a significant amount of product
returns, dependence on a single manufacturing facility and
potential disruptions of our manufacturing operations, the
inability to find strategic transaction opportunities or the
inability to successfully consummate or integrate a strategic
transaction, the inability to maintain or attract key personnel,
interruptions to our information technology systems, control by our
principal stockholders, and other factors indicated from time to
time in the company’s SEC reports, copies of which are available
upon request from the company’s investor relations department or
may be obtained at the SEC's web site (www.sec.gov). These risks and uncertainties should
be carefully considered before making an investment decision with
respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Schiff Nutrit (NYSE:WNI)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024